Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study
Background Adjuvant therapy may improve survival of patients with hepatocellular carcinoma (HCC) after curative resection. This study compared safety and efficacy outcomes between patients at high risk of recurrence who received different types of adjuvant therapy or no such therapy after hepatic re...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology 2023-10, Vol.58 (10), p.1043-1054 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1054 |
|---|---|
| container_issue | 10 |
| container_start_page | 1043 |
| container_title | Journal of gastroenterology |
| container_volume | 58 |
| creator | Li, Le Wu, Pei-Sheng Liang, Xiu-Mei Chen, Kang Zhang, Guan-Lan Su, Qi-Bin Huo, Rong-Rui Xie, Rong-Wei Huang, Shan Ma, Liang Zhong, Jian-Hong |
| description | Background
Adjuvant therapy may improve survival of patients with hepatocellular carcinoma (HCC) after curative resection. This study compared safety and efficacy outcomes between patients at high risk of recurrence who received different types of adjuvant therapy or no such therapy after hepatic resection for HCC.
Methods
Recurrence-free survival (RFS), overall survival, and adverse events were compared among patients who received adjuvant immune checkpoint inhibitors (ICIs) alone, ICIs with tyrosine kinase inhibitors (TKIs), or no adjuvant therapy between 13 March 2019 and 19 March 2022. This study was registered on ClinicalTrials.gov (NCT05221398).
Results
Of the 517 patients in final analysis, 432 (83.6%) received no adjuvant therapy, 53 (10.2%) received ICIs alone, and 32 (6.2%) received adjuvant ICIs and TKIs. During median follow-up of 34.0 months (IQR 27.8 to 41.6 months), RFS was significantly longer among patients who received either type of adjuvant therapy (25.2 months, 95%CI 16.4–34.0) than among those who received none (16.1 months, 95%CI 12.9–19.4), and this difference remained significant after propensity score matching (HR 0.52, 95%CI 0.35–0.76,
P
= 0.004). Overall survival was unaffected by either type of adjuvant therapy, while significant difference was observed between patients who received adjuvant therapy or not after propensity score matching (HR 0.31, 95%CI 0.17–0.59,
P
= 0.005). The rate of grade 3 or 4 adverse events was similar between the two types of adjuvant therapy.
Conclusions
ICIs alone or with TKIs may improve RFS of patients at high risk of HCC recurrence after curative resection. |
| doi_str_mv | 10.1007/s00535-023-02018-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2838251809</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A766760029</galeid><sourcerecordid>A766760029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-fee9f42ab263078ddca69ecaf4cef2c911e290cf448de97ffc747af73bf14bcb3</originalsourceid><addsrcrecordid>eNp9ktuKFDEQhhtR3HH1BbyQgDcr2GuSTp-8G5bxAIuKrN42merKdMbupM1hZJ_LFzTtrEdEQghUvv-nqviz7CGj54zS-pmntCzKnPIiXcqanN_KVkykUtlyfjtb0VaInLFanGT3vN9TygpaNnezk6IWJWe0XmVf1_0-HqQJRE9TNEhgQPg0W71UzKC3OljnifTegpYBe_JFh4EMejegIw4hOocGMFcOkfjoDvogxyQls_XBzuhk0AckA84yWMBxjKN0BKQDbewkydm795uPmzdXT54TSWZn_YywKJ6SKY5BA5rgNBCwg3WB-BD76_vZHSVHjw9u3tPsw4vN1cWr_PLty9cX68scRFWFXCG2SnC55VVB66bvQVYtglQCUHFoGUPeUlBCND22tVJQi1qqutgqJrawLU6zs6NvautzRB-6SftlBGnQRt_xpmh4yRraJvTxX-jeRmdSd4lqaVGJqvyN2skRO22UDU7CYtqt66qqK0r5Qp3_g0qnx0mDNah0qv8h4EcBpPV5h6qbnZ6ku-4Y7ZakdMekdCkp3fekdDyJHt10HLcT9j8lP6KRgOII-PRlduh-jfQf229mLM1f</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890364659</pqid></control><display><type>article</type><title>Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study</title><source>SpringerLink Journals - AutoHoldings</source><creator>Li, Le ; Wu, Pei-Sheng ; Liang, Xiu-Mei ; Chen, Kang ; Zhang, Guan-Lan ; Su, Qi-Bin ; Huo, Rong-Rui ; Xie, Rong-Wei ; Huang, Shan ; Ma, Liang ; Zhong, Jian-Hong</creator><creatorcontrib>Li, Le ; Wu, Pei-Sheng ; Liang, Xiu-Mei ; Chen, Kang ; Zhang, Guan-Lan ; Su, Qi-Bin ; Huo, Rong-Rui ; Xie, Rong-Wei ; Huang, Shan ; Ma, Liang ; Zhong, Jian-Hong</creatorcontrib><description>Background
Adjuvant therapy may improve survival of patients with hepatocellular carcinoma (HCC) after curative resection. This study compared safety and efficacy outcomes between patients at high risk of recurrence who received different types of adjuvant therapy or no such therapy after hepatic resection for HCC.
Methods
Recurrence-free survival (RFS), overall survival, and adverse events were compared among patients who received adjuvant immune checkpoint inhibitors (ICIs) alone, ICIs with tyrosine kinase inhibitors (TKIs), or no adjuvant therapy between 13 March 2019 and 19 March 2022. This study was registered on ClinicalTrials.gov (NCT05221398).
Results
Of the 517 patients in final analysis, 432 (83.6%) received no adjuvant therapy, 53 (10.2%) received ICIs alone, and 32 (6.2%) received adjuvant ICIs and TKIs. During median follow-up of 34.0 months (IQR 27.8 to 41.6 months), RFS was significantly longer among patients who received either type of adjuvant therapy (25.2 months, 95%CI 16.4–34.0) than among those who received none (16.1 months, 95%CI 12.9–19.4), and this difference remained significant after propensity score matching (HR 0.52, 95%CI 0.35–0.76,
P
= 0.004). Overall survival was unaffected by either type of adjuvant therapy, while significant difference was observed between patients who received adjuvant therapy or not after propensity score matching (HR 0.31, 95%CI 0.17–0.59,
P
= 0.005). The rate of grade 3 or 4 adverse events was similar between the two types of adjuvant therapy.
Conclusions
ICIs alone or with TKIs may improve RFS of patients at high risk of HCC recurrence after curative resection.</description><identifier>ISSN: 0944-1174</identifier><identifier>EISSN: 1435-5922</identifier><identifier>DOI: 10.1007/s00535-023-02018-2</identifier><identifier>PMID: 37452107</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Abdominal Surgery ; Adverse events ; Biliary Tract ; Care and treatment ; Colorectal Surgery ; Comparative analysis ; Gastroenterology ; Hepatocellular carcinoma ; Hepatology ; Hepatoma ; Immune checkpoint inhibitors ; Liver cancer ; Medicine ; Medicine & Public Health ; Original Article―Liver ; Pancreas ; Patient outcomes ; Prevention ; Protein-tyrosine kinase ; Surgical Oncology ; Survival ; Tyrosine</subject><ispartof>Journal of gastroenterology, 2023-10, Vol.58 (10), p.1043-1054</ispartof><rights>Japanese Society of Gastroenterology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. Japanese Society of Gastroenterology.</rights><rights>COPYRIGHT 2023 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-fee9f42ab263078ddca69ecaf4cef2c911e290cf448de97ffc747af73bf14bcb3</citedby><cites>FETCH-LOGICAL-c466t-fee9f42ab263078ddca69ecaf4cef2c911e290cf448de97ffc747af73bf14bcb3</cites><orcidid>0000-0002-1494-6396</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00535-023-02018-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00535-023-02018-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37452107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Le</creatorcontrib><creatorcontrib>Wu, Pei-Sheng</creatorcontrib><creatorcontrib>Liang, Xiu-Mei</creatorcontrib><creatorcontrib>Chen, Kang</creatorcontrib><creatorcontrib>Zhang, Guan-Lan</creatorcontrib><creatorcontrib>Su, Qi-Bin</creatorcontrib><creatorcontrib>Huo, Rong-Rui</creatorcontrib><creatorcontrib>Xie, Rong-Wei</creatorcontrib><creatorcontrib>Huang, Shan</creatorcontrib><creatorcontrib>Ma, Liang</creatorcontrib><creatorcontrib>Zhong, Jian-Hong</creatorcontrib><title>Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study</title><title>Journal of gastroenterology</title><addtitle>J Gastroenterol</addtitle><addtitle>J Gastroenterol</addtitle><description>Background
Adjuvant therapy may improve survival of patients with hepatocellular carcinoma (HCC) after curative resection. This study compared safety and efficacy outcomes between patients at high risk of recurrence who received different types of adjuvant therapy or no such therapy after hepatic resection for HCC.
Methods
Recurrence-free survival (RFS), overall survival, and adverse events were compared among patients who received adjuvant immune checkpoint inhibitors (ICIs) alone, ICIs with tyrosine kinase inhibitors (TKIs), or no adjuvant therapy between 13 March 2019 and 19 March 2022. This study was registered on ClinicalTrials.gov (NCT05221398).
Results
Of the 517 patients in final analysis, 432 (83.6%) received no adjuvant therapy, 53 (10.2%) received ICIs alone, and 32 (6.2%) received adjuvant ICIs and TKIs. During median follow-up of 34.0 months (IQR 27.8 to 41.6 months), RFS was significantly longer among patients who received either type of adjuvant therapy (25.2 months, 95%CI 16.4–34.0) than among those who received none (16.1 months, 95%CI 12.9–19.4), and this difference remained significant after propensity score matching (HR 0.52, 95%CI 0.35–0.76,
P
= 0.004). Overall survival was unaffected by either type of adjuvant therapy, while significant difference was observed between patients who received adjuvant therapy or not after propensity score matching (HR 0.31, 95%CI 0.17–0.59,
P
= 0.005). The rate of grade 3 or 4 adverse events was similar between the two types of adjuvant therapy.
Conclusions
ICIs alone or with TKIs may improve RFS of patients at high risk of HCC recurrence after curative resection.</description><subject>Abdominal Surgery</subject><subject>Adverse events</subject><subject>Biliary Tract</subject><subject>Care and treatment</subject><subject>Colorectal Surgery</subject><subject>Comparative analysis</subject><subject>Gastroenterology</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatology</subject><subject>Hepatoma</subject><subject>Immune checkpoint inhibitors</subject><subject>Liver cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article―Liver</subject><subject>Pancreas</subject><subject>Patient outcomes</subject><subject>Prevention</subject><subject>Protein-tyrosine kinase</subject><subject>Surgical Oncology</subject><subject>Survival</subject><subject>Tyrosine</subject><issn>0944-1174</issn><issn>1435-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9ktuKFDEQhhtR3HH1BbyQgDcr2GuSTp-8G5bxAIuKrN42merKdMbupM1hZJ_LFzTtrEdEQghUvv-nqviz7CGj54zS-pmntCzKnPIiXcqanN_KVkykUtlyfjtb0VaInLFanGT3vN9TygpaNnezk6IWJWe0XmVf1_0-HqQJRE9TNEhgQPg0W71UzKC3OljnifTegpYBe_JFh4EMejegIw4hOocGMFcOkfjoDvogxyQls_XBzuhk0AckA84yWMBxjKN0BKQDbewkydm795uPmzdXT54TSWZn_YywKJ6SKY5BA5rgNBCwg3WB-BD76_vZHSVHjw9u3tPsw4vN1cWr_PLty9cX68scRFWFXCG2SnC55VVB66bvQVYtglQCUHFoGUPeUlBCND22tVJQi1qqutgqJrawLU6zs6NvautzRB-6SftlBGnQRt_xpmh4yRraJvTxX-jeRmdSd4lqaVGJqvyN2skRO22UDU7CYtqt66qqK0r5Qp3_g0qnx0mDNah0qv8h4EcBpPV5h6qbnZ6ku-4Y7ZakdMekdCkp3fekdDyJHt10HLcT9j8lP6KRgOII-PRlduh-jfQf229mLM1f</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Li, Le</creator><creator>Wu, Pei-Sheng</creator><creator>Liang, Xiu-Mei</creator><creator>Chen, Kang</creator><creator>Zhang, Guan-Lan</creator><creator>Su, Qi-Bin</creator><creator>Huo, Rong-Rui</creator><creator>Xie, Rong-Wei</creator><creator>Huang, Shan</creator><creator>Ma, Liang</creator><creator>Zhong, Jian-Hong</creator><general>Springer Nature Singapore</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1494-6396</orcidid></search><sort><creationdate>20231001</creationdate><title>Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study</title><author>Li, Le ; Wu, Pei-Sheng ; Liang, Xiu-Mei ; Chen, Kang ; Zhang, Guan-Lan ; Su, Qi-Bin ; Huo, Rong-Rui ; Xie, Rong-Wei ; Huang, Shan ; Ma, Liang ; Zhong, Jian-Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-fee9f42ab263078ddca69ecaf4cef2c911e290cf448de97ffc747af73bf14bcb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abdominal Surgery</topic><topic>Adverse events</topic><topic>Biliary Tract</topic><topic>Care and treatment</topic><topic>Colorectal Surgery</topic><topic>Comparative analysis</topic><topic>Gastroenterology</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatology</topic><topic>Hepatoma</topic><topic>Immune checkpoint inhibitors</topic><topic>Liver cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article―Liver</topic><topic>Pancreas</topic><topic>Patient outcomes</topic><topic>Prevention</topic><topic>Protein-tyrosine kinase</topic><topic>Surgical Oncology</topic><topic>Survival</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Le</creatorcontrib><creatorcontrib>Wu, Pei-Sheng</creatorcontrib><creatorcontrib>Liang, Xiu-Mei</creatorcontrib><creatorcontrib>Chen, Kang</creatorcontrib><creatorcontrib>Zhang, Guan-Lan</creatorcontrib><creatorcontrib>Su, Qi-Bin</creatorcontrib><creatorcontrib>Huo, Rong-Rui</creatorcontrib><creatorcontrib>Xie, Rong-Wei</creatorcontrib><creatorcontrib>Huang, Shan</creatorcontrib><creatorcontrib>Ma, Liang</creatorcontrib><creatorcontrib>Zhong, Jian-Hong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Le</au><au>Wu, Pei-Sheng</au><au>Liang, Xiu-Mei</au><au>Chen, Kang</au><au>Zhang, Guan-Lan</au><au>Su, Qi-Bin</au><au>Huo, Rong-Rui</au><au>Xie, Rong-Wei</au><au>Huang, Shan</au><au>Ma, Liang</au><au>Zhong, Jian-Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study</atitle><jtitle>Journal of gastroenterology</jtitle><stitle>J Gastroenterol</stitle><addtitle>J Gastroenterol</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>58</volume><issue>10</issue><spage>1043</spage><epage>1054</epage><pages>1043-1054</pages><issn>0944-1174</issn><eissn>1435-5922</eissn><abstract>Background
Adjuvant therapy may improve survival of patients with hepatocellular carcinoma (HCC) after curative resection. This study compared safety and efficacy outcomes between patients at high risk of recurrence who received different types of adjuvant therapy or no such therapy after hepatic resection for HCC.
Methods
Recurrence-free survival (RFS), overall survival, and adverse events were compared among patients who received adjuvant immune checkpoint inhibitors (ICIs) alone, ICIs with tyrosine kinase inhibitors (TKIs), or no adjuvant therapy between 13 March 2019 and 19 March 2022. This study was registered on ClinicalTrials.gov (NCT05221398).
Results
Of the 517 patients in final analysis, 432 (83.6%) received no adjuvant therapy, 53 (10.2%) received ICIs alone, and 32 (6.2%) received adjuvant ICIs and TKIs. During median follow-up of 34.0 months (IQR 27.8 to 41.6 months), RFS was significantly longer among patients who received either type of adjuvant therapy (25.2 months, 95%CI 16.4–34.0) than among those who received none (16.1 months, 95%CI 12.9–19.4), and this difference remained significant after propensity score matching (HR 0.52, 95%CI 0.35–0.76,
P
= 0.004). Overall survival was unaffected by either type of adjuvant therapy, while significant difference was observed between patients who received adjuvant therapy or not after propensity score matching (HR 0.31, 95%CI 0.17–0.59,
P
= 0.005). The rate of grade 3 or 4 adverse events was similar between the two types of adjuvant therapy.
Conclusions
ICIs alone or with TKIs may improve RFS of patients at high risk of HCC recurrence after curative resection.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>37452107</pmid><doi>10.1007/s00535-023-02018-2</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-1494-6396</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0944-1174 |
| ispartof | Journal of gastroenterology, 2023-10, Vol.58 (10), p.1043-1054 |
| issn | 0944-1174 1435-5922 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2838251809 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Abdominal Surgery Adverse events Biliary Tract Care and treatment Colorectal Surgery Comparative analysis Gastroenterology Hepatocellular carcinoma Hepatology Hepatoma Immune checkpoint inhibitors Liver cancer Medicine Medicine & Public Health Original Article―Liver Pancreas Patient outcomes Prevention Protein-tyrosine kinase Surgical Oncology Survival Tyrosine |
| title | Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T08%3A34%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20immune%20checkpoint%20inhibitors%20associated%20with%20higher%20recurrence-free%20survival%20in%20postoperative%20hepatocellular%20carcinoma%20(PREVENT):%20a%20prospective,%20multicentric%20cohort%20study&rft.jtitle=Journal%20of%20gastroenterology&rft.au=Li,%20Le&rft.date=2023-10-01&rft.volume=58&rft.issue=10&rft.spage=1043&rft.epage=1054&rft.pages=1043-1054&rft.issn=0944-1174&rft.eissn=1435-5922&rft_id=info:doi/10.1007/s00535-023-02018-2&rft_dat=%3Cgale_proqu%3EA766760029%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2890364659&rft_id=info:pmid/37452107&rft_galeid=A766760029&rfr_iscdi=true |